Susquehanna Portfolio Strategies LLC Sells 940 Shares of Masimo Co. (NASDAQ:MASI)

Susquehanna Portfolio Strategies LLC lessened its stake in shares of Masimo Co. (NASDAQ:MASI) by 1.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 71,789 shares of the medical equipment provider’s stock after selling 940 shares during the quarter. Susquehanna Portfolio Strategies LLC owned about 0.13% of Masimo worth $9,041,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Riverview Trust Co bought a new stake in shares of Masimo during the 1st quarter worth about $25,000. GAMMA Investing LLC boosted its stake in shares of Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after acquiring an additional 111 shares in the last quarter. Parallel Advisors LLC boosted its stake in Masimo by 48.3% during the 4th quarter. Parallel Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $52,000 after purchasing an additional 145 shares during the period. Lazard Asset Management LLC boosted its stake in Masimo by 5,730.0% during the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 573 shares during the period. Finally, HHM Wealth Advisors LLC boosted its stake in Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after purchasing an additional 125 shares during the period. Institutional investors own 85.96% of the company’s stock.

Masimo Trading Up 0.1 %

Shares of MASI opened at $133.20 on Friday. Masimo Co. has a 1 year low of $75.22 and a 1 year high of $153.93. The company has a current ratio of 2.09, a quick ratio of 1.15 and a debt-to-equity ratio of 0.55. The stock has a 50 day simple moving average of $116.67 and a 200-day simple moving average of $124.97. The stock has a market cap of $7.08 billion, a PE ratio of 90.61 and a beta of 0.98.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The firm had revenue of $496.30 million during the quarter, compared to analysts’ expectations of $493.92 million. During the same period last year, the firm posted $0.62 EPS. The business’s revenue was up 9.0% on a year-over-year basis. On average, sell-side analysts predict that Masimo Co. will post 3.87 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on MASI shares. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Friday, September 20th. Piper Sandler increased their target price on Masimo from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $144.67.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.